viewOpen Orphan PLC

New contract build global footprint, says Venn Life Sciences Holdings plc CEO

Venn Life Sciences Holdings plc (LON:VENN) says the newly awarded €2.8mln contract allows the group to “build a proper international footprint”.
The contract is with a European biotech group to carry out a phase II trial.
Chief executive Tony Richardson says “it’s the kind of business we’ve really been pursuing.”
“It’s a good up-and-coming European bio-tech client operating across many countries,” he adds.
Venn hails the deal and says vendor qualification is a significant milestone for its Interactive Response Technology and represents an exciting opportunity to grow a global account.
“The deal allows us to build a proper international footprint,” says Richardson.
“It’s an exciting area to be working in and fits really well with current capabilities.”
The trial is for an immunotherapeutic treatment for Multiple Sclerosis, involving patients in six countries across Europe and starts in October.

Quick facts: Open Orphan PLC

Price: 28.75 GBX

Market: AIM
Market Cap: £192.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...


Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

on 30/9/20

2 min read